MSD Korea to recruits subjects with advanced multiple myeloma

Published: 2009-01-09 06:59:00

Updated: 2009-01-09 06:59:00

MSD Korea said on January 7 that it will conduct its local phase 3 and Phase 2b Studies in seven universities hospitals for Merck & Co’s Zolinza (vorinostat), Merck’s oral histone deacetylase (HDAC) inhibitor, in patients with advanced multiple myeloma.

Results from two Phase 1 studies of ZOLINZA administered in combination with bortezomib showed early anti-tumor activity in patients with re...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.